7Phase Ib/II Study of APG-1252 in Patients with Myelofibrosis who Progressed After Initial Therapy
MD Anderson Study Status
The study is a designed to evaluate safety and activity of APG-1252 when administered as monotherapy and in combination with ruxolitinib in previously ruxolitinib treated myelofibrosis patients.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.